Evidence map›Paper›PMID 40723906›Full record

ArticleBiomolecules2025

Co-Inhibition of PARP and STAT3 as a Promising Approach for Triple-Negative Breast Cancer.

Changyou Shi, Li Pan, Satomi Amano, Mei-Yi Wu, Chenglong Li, Jiayuh Lin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. STAT3 signaling inhibitors for cancer treatment.Trends in pharmacological sciences · 2026
    Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Changyou ShiDepartment of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Li PanDepartment of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Satomi AmanoDepartment of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.ORCID 0009-0001-0916-1754
Mei-Yi WuDepartment of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Chenglong LiDepartment of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL 32611, USA.
Jiayuh LinDepartment of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.ORCID 0000-0002-5618-8781

Funding

Regulation of Type I Interferon Pro-tumor Effects in Breast CancerR01CA255996 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Mei-Yi Wu · 2021 to 2026
$1.8M
Dual inhibition of PARP and STAT3 as a novel therapeutic approach for triple-negative breast cancerR21CA270591 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI LIN, JIAYUH · 2024 to 2025
$412k
NCI NIH HHS R01 CA255996NCI NIH HHS R21 CA270591NIH/NCI R21 1R21CA270591-01A1
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is a highly aggressive subtype known for its rapid metastatic potential. Despite its severity, treatment options for TNBC remain limited. Olaparib, an FDA-approved PARP inhibitor, has been used to treat germline

Indexed as

PhthalazinesPoly(ADP-ribose) Polymerase InhibitorsSTAT3 Transcription FactorTriple Negative Breast NeoplasmsAnthraquinonesCell Line, TumorCell MovementCell ProliferationFemaleHumansInterleukin-6PiperazinesSignal TransductionSulfonamidesAnthraquinonesIL6 protein, humanInterleukin-6LLL12 compoundolaparibPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsSTAT3 protein, humanSTAT3 Transcription FactorSulfonamidesBRCAIL-6/STAT3 signalingPARP inhibitorSTAT3 inhibitiontriple-negative breast cancer (TNBC)

Identifiers

PMID40723906
PMCPMC12292728

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.